Kymera Therapeutics, Inc.
KYMR
$81.21
$1.612.02%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -16.70% | -50.05% | -49.51% | -25.85% | -40.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -16.70% | -50.05% | -49.51% | -25.85% | -40.11% |
| Cost of Revenue | 31.77% | 37.56% | 39.10% | 38.85% | 27.06% |
| Gross Profit | -43.58% | -94.88% | -104.18% | -83.04% | -74.84% |
| SG&A Expenses | 7.32% | 10.02% | 9.33% | 15.09% | 15.43% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.65% | 31.58% | 32.46% | 33.50% | 24.44% |
| Operating Income | -34.61% | -68.18% | -72.63% | -60.72% | -55.08% |
| Income Before Tax | -39.08% | -76.22% | -74.49% | -55.82% | -52.32% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.08% | -76.22% | -74.49% | -55.82% | -52.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.08% | -76.22% | -74.49% | -55.82% | -52.32% |
| EBIT | -34.61% | -68.18% | -72.63% | -60.72% | -55.08% |
| EBITDA | -35.13% | -69.80% | -72.70% | -60.43% | -54.45% |
| EPS Basic | -24.00% | -54.48% | -44.10% | -23.89% | -17.79% |
| Normalized Basic EPS | -25.46% | -57.29% | -48.38% | -27.43% | -15.03% |
| EPS Diluted | -24.00% | -54.48% | -44.10% | -23.89% | -17.79% |
| Normalized Diluted EPS | -25.46% | -57.29% | -48.38% | -27.43% | -15.03% |
| Average Basic Shares Outstanding | 12.62% | 17.74% | 21.45% | 25.72% | 28.48% |
| Average Diluted Shares Outstanding | 12.62% | 17.74% | 21.45% | 25.72% | 28.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |